MOSAIC is a five-year global project to accelerate introduction and scale-up of new biomedical prevention products and expedite their availability, acceptance, uptake, and impact in PEPFAR programs to help individuals, especially women, prevent HIV and other infectious diseases.
Today is the 10th anniversary of International Day of the Girl Child, a time to celebrate girl changemakers and leaders, focus attention on issues that matter to girls, and amplify girls’ voices on the global stage. To mark the occasion, MOSAIC staff reflect on their own girlhood and give advice to their former selves.
Continue Reading
Any two people can use Empathways together. But in the global HIV care, prevention, and treatment community, Jhpiego has leveraged an adapted version of the tool, using it to bring together groups of people who have relationships that are uncomfortable at best, and downright traumatizing at worst.
Continue Reading
For the MOSAIC project team, the AIDS 2022 conference set the stage for embracing the introduction of new biomedical HIV prevention products and generating evidence on how to support choice and effective use. We attended the conference virtually and took away three key messages that resonate with our work on MOSAIC.
Continue Reading
Since oral PrEP was first approved for use in 2012, dozens of countries have approved the product and use is expanding. But the pace of scale-up has been slower than expected and PrEP remains out of reach for many who may benefit from it.
Continue Reading
In this photo story, MOSAIC NextGen Squad representatives introduce themselves through their stories. They share their passions, what led them to work in HIV prevention, their thoughts on MOSAIC, and their hopes and dreams for the future.
Continue Reading
The future of HIV prevention is here. Injectable cabotegravir (CAB) is the most effective, longest-acting option for avoiding the virus. Until now, pre-exposure prophylaxis (or PrEP) medicine taken to prevent HIV has only been available as an oral pill that must be taken daily. CAB needs to be injected only once every two months.
Continue Reading
This workshop will explore what is needed to ensure that introductory research and programs are strategically designed, user-centered, and appropriately resourced to support successful rollout of CAB PrEP.
Continue Reading
Sub-Saharan Africa is home to 25.3 million (67%) of the global total of 37.7 million people living with HIV infection (UNAIDS 2021). To control the epidemic in Africa, it is essential that solutions for Africa be generated and implemented in Africa.
Continue Reading
As we move toward a multi-product HIV prevention market, adolescent girls and young women must be empowered to choose an HIV prevention product that meets their needs.
Continue Reading
With the dapivirine vaginal ring and injectable cabotegravir poised to join oral pre-exposure prophylaxis (PrEP) as safe, effective HIV prevention products, people seeking an HIV prevention method that works for them will soon have real choices.
Continue Reading